Opioids are a class of drugs derived from a specialty variety of the poppy, known as the opium poppy or Papaver somniferum, that cause great euphoria and analgesic qualities, which are those that reduce pain by blocking pain signals from being successfully relayed from areas of discomfort and the brain via the central nervous system.
Without going into the details of how this came to be, the United States. is facing an ongoing rash of opioid use that originated from the overprescription of high-dosage opioids branded as being non-abusable and better alternatives to existing opioids because they were allegedly so hard to get hooked on, though, as we all know, this ended up being a lie.
Various governments across the United States, including the state of Oklahoma, which was recently the host of a trial whereby a couple of major players in developing the opioid crisis ended up having to pay many hundreds of millions of dollars to the state in damages for its wrongdoings.
Now, at least according to existing regulatory agency filings that just recently became visible to the world at large, six major members of the “big pharma” group, or the top of the charts in terms of pharmaceutical companies active across the United States, are being investigated by federal prosecutors for transporting major quantities of prescription opioids created in a pharmaceutical manufacturing warehouse to pharmacies and doctors around the United States, ultimately making the current depth of the opioid crisis worse than it would have been without the actions of these six businesses.
A handful of companies in pharmacy have received subpoenas, or requests for information, from the Eastern District of New York’s United States Attorney’s office, which include McKesson Corp, Amneal Pharmaceuticals Inc, Mallinckrodt Plc, Johnson & Johnson, and the Israel-based Teva Pharmaceutical Industries Ltd.
New of this investigation first surfaced yesterday, on Tuesday, Nov. 26, 2019, following a report from the Wall Street Journal.
According to the aforementioned report, these federal prosecutors in New York’s Eastern District are in the process of planning a number of other subpoenas to go out to pharmaceutical industry competitors that made mistakes as far as distributing opioids and otherwise handling the drug or shaping the policies upon which the opioid crisis was effectively accelerated. AmerisourceBergen Corp was also a recipient of a subpoena from the same office as mentioned above, though the company didn’t sound keen on going into details.